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Summary Postmenopausal hormone replacement therapy (HRT) has been linked to
asthma in women, however, with inconsistent conclusions. This study examined the
association of HRTwith bronchial hyper-responsiveness (BHR). Eighty-five postmeno-
pausal women completed a women-specific questionnaire and underwent methacho-
line challenge testing according to the protocol of the European community
respiratory health survey. Associations of HRT use with BHR (based on a 20% fall in
FEV1), mild BHR (10% fall in FEV1) or dichotomized dose–response slopes were
analyzed by logistic regression, controlling for age, education, smoking and
overweight. The 27 HRT users were less likely to show BHR compared to the 58
non-users (11% vs. 41%), multiply adjusted odds ratio (95% confidence interval) 0.12
(0.03, 0.55). Results for dose–response slopes were similar, while mild BHR showed no
association with HRT use. These results point to a relaxing effect of estrogens on
bronchial smooth muscle.







Postmenopausal women using hormone replace-
ment therapy (HRT) have been found to be at
higher risk of first onset of asthma compared to
non-users.1 For lung function and severity of
asthma symptoms, contradictory results have been
reported.2–6 This study examined the association of
HRT use with bronchial hyper-responsiveness (BHR)
after methacholine challenge.
Methods
In 1991/92, a representative population sample in
Erfurt, Germany participated in the WHO-MONICA
Project, which had been initiated to monitor trends
and determinants of cardiovascular disease mor-
bidity and mortality in 27 countries.7 The 20–64-
year-old study population, 629 women and 659
men,8 were simultaneously examined following the
protocol of the European Community Respiratory
Health Survey (ECRHS).9
For the MONICA survey, a women-specific ques-
tionnaire on menstruation, current use of sex
hormones, and history of gynecological surgery
was administered. We categorized the women as
post-, peri-, or premenopausal (the algorithm for
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categorization can be obtained from authors), and
the post- and perimenopausal women as current
users or non-users of HRT.
The ECRHS protocol comprised an interview and
lung function measurements with methacholine
challenge testing (MCT).10 Participants whose
FEV1 was at least 70% of the predicted value and
more than 1.5 l and who gave consent underwent
MCT, unless they had angina pectoris or epilepsy, or
were using beta-receptor blockers. BHR (mild BHR)
was diagnosed, if after inhalation of up to 2.0mg
methacholine, the decrease in FEV1 reached 20%
(10%).11 Participants with smaller change in FEV1
were considered normoreactive. The dose–re-
sponse slope for FEV1 change per mg methacholine
(%/mg)12 was dichotomized by cut-offs of 0.1 and
0.05%/mg.
Fisher’s exact test, and general linear and
logistic regression models were used to test
differences in participant characteristics and asso-
ciations of postmenopausal HRT use with BHR and
slope cut-offs (software: SAS 8.1, SAS Institute
Inc.). The multiply adjusted model included age
(o45/45–54/>54 years), smoking (never, past,
current), age o20 years at the end of education,
and overweight (body mass index X25 kg/m2). All
tests were two-sided and statistical significance
was defined as Po0:05 for description.
Results
Women-specific information was available for 506
of the women. Information on airway reactivity was
available for only 333 women, due to exclusion
criteria and refusal. Of these, 27 were HRT users,
11 (41%) of which were hysterectomized. There
were 58 postmenopausal non-users and 19 perime-
nopausal non-users. HRT users were significantly
younger and less often overweight than postmeno-
pausal non-users. They tended to have longer
education and more frequent exposure to passive
smoking. After controlling for age, only the
difference in overweight was significant. The age-
standardized baseline FEV1 was 2.81 vs. 2.65 l for
HRT users vs. non-users (P ¼ 0:060).
BHR was less frequent among HRT users com-
pared to non-users (11% vs. 41%) (Table 1). The age-
adjusted odds ratio (95% confidence intervalFCI)
was 0.18 (0.05, 0.66), and the multiply adjusted OR
(95% CI) 0.12 (0.03, 0.55). Both dichotomized dose–
response slopes were associated with HRT use:
slope >0.1%/mg OR (95% CI) 0.13 (0.03, 0.65); slope
>0.05%/mg OR (95% CI) 0.31 (0.10, 0.93). Mild BHR
did not show a strong association with HRT use.
Similar results were found when dose–response
slope was used as a continuous variable, when
perimenopausal women without HRTwere included
in the group of non-users (because under HRT,
perimenopausal women cannot be differentiated
from postmenopausal women), or when baseline
FEV1 was included in the model (FEV1, an inter-
mediate factor between HRT use and BHR, should
not be included in the standard model).
Discussion
These results are comparable to a study that
examined 36 non-asthmatic postmenopausal wo-
men before and 4–6 weeks after the initiation of
estrogen replacement and that found a significantly
smaller maximal decline in FEV1 upon histamine
challenge during HRT use.13
Estrogens, the main components of HRT, have a
relaxing effect on vascular smooth muscle.14 They
also seem to have a relaxing effect on smooth
muscle in bronchi, and there is evidence from
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Table 1 Postmenopausal hormone replacement therapy (HRT) and bronchial hyper-responsiveness (BHR) in
85 women.
HRT Effect estimate
Users Non-users Age-adjusted Multiply adjustedn
(N ¼ 27) (%) (N ¼ 58) (%) OR (95% CI) OR (95% CI)
BHR 11 41 0.19 (0.05, 0.72) 0.12 (0.03, 0.55)
Mild BHR 52 66 0.75 (0.22, 1.49) 0.85 (0.29, 2.45)
Slope >0.1w 11 37 0.24 (0.06, 0.91) 0.13 (0.03, 0.65)
Slope
>0.05w
33 60 0.31 (0.12, 0.85) 0.31 (0.10, 0.93)
MONICA and ECRHS Erfurt, Germany, 1991/92.OR (95% CI) odds ratio (95% confidence interval).
nAdjusted for age, smoking, age at end of education, overweight.
wIn percent FEV1 change per mg methacholine.
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experimental studies that estrogens diminish max-
imum bronchial constriction upon challenge.15–18
While our results seem to contrast with studies that
found an adverse effect of HRT on onset or
symptoms of asthma,4–6 this could be explained
by the complexity of the underlying mechanisms for
asthma and the contrasting effects of estrogens on
these mechanisms, e.g. relaxation of smooth
muscle and modulation of inflammatory re-
sponse.19,20 This ambiguous effect of estrogens is
known for cardiovascular disease,21 and could hold
true for asthma.
A limitation of this study is the restriction to
women who are healthy in terms of lung function,
angina pectoris, and epilepsy, and who agreed to
have MCT (note: the postmenopausal women in the
MONICA survey without MCT were older and had
lower age-standardized baseline FEV1 than women
with MCT, but the association of HRT use with FEV1
was similar among women with and without MCT).
The cross-sectional design leaves the possibility of
an inverse association, i.e. BHR causes non-initia-
tion or cessation of HRT. There may be residual
confounding by body weight22 or determinants of
HRT use that were not captured in the question-
naire.23 It is not known whether HRTcontained only
estrogens or whether progesterone was added, but
one can assume that at least the hysterectomized
HRT users (40%) took estrogens only.
In conclusion, postmenopausal HRT seems to be
negatively associated with BHR after MCT, which
points to a relaxing effect of estrogens on bronchial
smooth muscle.
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